FLAGU - FLAGU STOCK NEWS

Welcome to our dedicated page for FLAGU news (Ticker: FLAGU), a resource for investors and traders seeking the latest updates and insights on FLAGU stock.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage immuno-oncology company, specializes in developing targeted immunotherapies for cancer treatment. With proprietary technology utilizing stem cells to deliver anti-tumor payloads, Calidi aims to revolutionize cancer therapy. Led by CEO Allan Camaisa, the company's cutting-edge platforms, NeuroNova, and SuperNova, focus on high-grade gliomas and solid tumors, offering promising clinical results. Following a successful business combination with First Light Acquisition Group, Calidi is well-positioned to advance its innovative therapies and continue its mission to eradicate cancer.

09/13/2023 05:50 AM

News

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Rhea-AI Summary

Calidi Biotherapeutics completes business combination with First Light Acquisition Group, securing approximately $28 million in gross proceeds. Calidi also secures forward purchase agreement for up to $10 million and intends to enter into a purchase agreement for up to $50 million. Common stock and warrants to commence trading on NYSE on September 13.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments

Rhea-AI Summary

First Light Acquisition Group anticipates completing its business combination with Calidi Biotherapeutics on September 12, 2023. Gross proceeds made available to Calidi Biotherapeutics from the transaction will total approximately $28 million. Calidi also secured a forward purchase agreement for up to $10 million. Common stock and warrants of Calidi approved for listing on the New York Stock Exchange American under the ticker symbols “CLDI” and “CLDI WS,” respectively, and expected to begin trading on September 13, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.66%

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer

Rhea-AI Summary

Calidi Biotherapeutics secures $25 million in Series B funding led by Jackson Investment Group and Calidi Cure

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.57%

FAQ

What is Calidi Biotherapeutics known for?

Calidi Biotherapeutics is a clinical-stage immuno-oncology company specializing in developing targeted immunotherapies for cancer treatment.

What are the key platforms of Calidi Biotherapeutics?

Calidi's key platforms are NeuroNova and SuperNova, focusing on high-grade gliomas and solid tumors, respectively.

Who leads Calidi Biotherapeutics?

Calidi Biotherapeutics is led by CEO Allan Camaisa, who is dedicated to advancing innovative cancer therapies.

What is the recent achievement of Calidi Biotherapeutics?

Calidi successfully completed a business combination with First Light Acquisition Group, positioning them to further develop their immunotherapy platforms.